OPENING KEYNOTES

Whaijen Soo, M.D., Ph.D., Senior Vice President, Medical Research, Biogen Idec
With fast growth in commercial opportunities, R&D talent pools and cost effectiveness, and improvement in business environment, China can no longer be ignored by any biopharmaceutical companies in their expansion of global reach. The strategic planning process for entering China, remaining questions, as well as challenges for implementation, will be discussed.

• Strategic overview of the pharmaceutical value chain environment
• Evaluating the economic, political and business opportunities and obstacles
• Regulatory environment in the U.S. and China:1) SFDA 2)Intellectual property
• Portfolio considerations
• Execution challenges

10:15 Networking Coffee Break

Guoxin Zhu, Ph.D., CSO / Head of China Chemistry, Discovery Chemistry Research & Technology, Eli Lilly Asia, Inc., Shanghai Rep. Office
Multinational corporations are increasingly realizing that China is not just a vast market or even a production base —  it is a critical focus for research and development (R&D) functions as well. This session will discuss the opportunities and challenges conducting pharmaceutical R&D in China.

• Current realities of drug discovery & development
• The role of Chinese CROs
• Pharma R&D models in China
• Transition trend for global pharmaceutical R&D
• Lilly current R&D in China

• Strike proper balance between bold experiments and carefully planned execution
• Strengthen R&D partnership through alliance management and coordination
• Analyze recent trends in strategic sourcing of R&D services in China

Keynote Q&A with Audience

Samantha Du, Ph.D., Managing Director, Hutchison MediPharma Ltd., Chief Scientific Officer & Executive Vice President, Hutchison China Meditech Limited
The capital- and time-consuming nature of drug R&D has become a huge problem for the healthcare industry. That coupled with the high attrition rate has threatened to dampen the enthusiasm for the industry to make large investments from earlier discovery to proof of concept. However, the recent ascent of China in the world economy created opportunities for the industry to re-think its strategy in reducing time and cost by taking advantages of China resources. This presentation will share HMPL’s R&D strategies and how to best manage R&D operations in China to maximize productivity. The author will also describe the opportunities and risks in investing in China. This presentation will:

• Highlight a successful story of a drug R&D company growing from a start-up to a leading R&D company in China and also an int’l public company within four years
• Provide a real case study by analyzing China strategies and best ulitizing China resources for the successful global drug development
• Share first-hand experiences in drug R&D development and company management in China

Lorenz Ng, M.D ., Managing Partner, Global Ng Associates, LLC and former Vice President, Research & Alliance & Business Development, Asia Pacific, Eli Lilly & Co. (Asia)
The need to increase productivity at lower cost is driving big Pharmas to capture the current arbitrage potential of Asia through outsourcing/contract work. A second wave is building with players actively seekingstrategic alliances and partnership opportunities globally across the R&D value chain. Will this meta-national innovation process become the new imperative for survival in the 21st Century? Will this lead to “creative destruction” of our vertically-integrated multi-national model and emergence of a new model with meta-national advantage?

Michael N. Liebman, Ph.D., Executive Director, Windber Research Institute
Significant opportunities exist within China and Taiwan for development of research and development facilities in both China and Taiwan, but issues exist because of regulatory and cultural perspectives that need to be considered in both the planning and execution of such activities, especially as they may differ amongst molecular, clinical and computational research areas.

• How to evaluate risk vs. opportunity in each of the three areas: molecular research, clinical research and computational research 
• How to explore partnerships to facilitate success in working in China and Taiwan 
• How to manage US vs. international regulatory issues in working in China and Taiwan

Andrew Branca, SVP, Strategic Research, Cambridge Healthtech Associates

• Needs in translational medicine & biomarker validation
• Strategic opportunities in China
• Establishing requirements and specifications for potential partners and vendors
• Approaches to identifying and assessing potential partners and vendors
• Challenges to establishing relationships in emerging markets – regulatory issues (including sample import/export), logistical and distance considerations, cultural differences, and other considerations affecting planning

4:45 Interactive Panel Discussion #2:

Partnership and Outsourcing Deals in China – Successes and Failures

• Overcoming cultural differences and infrastructure obstacles
• Key cost drivers and less obvious budgetary pitfalls
• Choosing a worthy partner and performing capability assessment
• Making the most of your partnerships
• Addressing IP concerns and ensuring patent protection
• Training staff and transferring technology
• Effectively controlling quality

Panelists:

	Mao Mao, M.D., Ph.D.,  Associate Director/China Project Liaison, Oncology Clinical Research, Merck Research Laboratories		Michael N. Liebman, Ph.D., Executive Director, Windber Research Institute
	Ming Guo,  Vice President, Pharmaceutical Science and Manufacturing, Ascenta Therapeutics, Inc.		Rajiv Gulati,  Director, China-India Strategy, Corporate Strategic Planning, Eli Lilly & Co.
	Lorenz Ng, M.D., Ph.D.,  former Vice President, Research & Alliance & Business Development, Asia Pacific, Eli Lilly & Co (Asia)